QuadraMed, LifeMed ID Form Patient Identity Joint Venture

RESTON, Va.--QuadraMed Corporation today announced the company has entered into a joint venture called “Better Together” with LifeMed ID, Inc. The new partnership combines QuadraMed’s top ranked Enterprise Master Patient Index (EMPI) solution with LifeMed ID’s leading deterministic patient identity authentication technology providing a comprehensive solution that essentially eliminates many root causes of patient misidentification.

QuadraMed’s EMPI and data management services eliminate duplicate records and link fragmented patient records within and across each data source in a health system. This establishes a strong platform on which to deploy LifeMed ID to positively validate and authenticate every patient to maintain consistent identity across disparate systems. LifeMed ID validates most all ID tokens to authenticate a patient. Once a patient’s demographics and tokens are verified, the identity token is permanently linked to their medical record and can be used at every participating facility using point of service terminals regardless of which EHR, practice management or registration system is in use. Patient registration is automated within 30 seconds and avoids time-consuming and repetitive registration processes at each point of care.“Better Together is a win for healthcare providers and patients alike,” said Vicki Wheatley, Executive Vice President of EMPI at QuadraMed. “Our joint venture with LifeMed ID provides the ability to streamline identity validation, automate workflow processes, and decrease end-user administrative costs. Healthcare organizations can now be assured that every patient will have one true identity that is permanently linked to the correct medical record across all points of care. We call this concept, ‘enroll once, engage many’.”

Clinicians will be able to provide care with confidence knowing that they have the right medical record for each patient. The healthcare enterprise will operate more efficiently and the risk of medical identity fraud is drastically reduced. “Accurate patient identity is the foundation to optimizing workflow processes, patient safety, and satisfaction,” said David Batchelor, Chief Executive Officer at LifeMed ID. “The combination of deterministic and algorithmic identification methods establishes near 100 percent accurate patient identity.”

To learn more about QuadraMed EMPI, visit www.quadramed.com, and more information about LifeMed ID is available at www.lifemedid.com.

About QuadraMed Corporation

QuadraMed® is a leading provider of award-winning healthcare technologies and services that improve the safety, quality and efficiency of patient care. Founded in 1993, QuadraMed provides proven, flexible solutions that help make our clients successful by streamlining processes, increasing productivity, and driving positive patient outcomes. Behind the Company’s products and services is a staff of 475 professionals who support clients at over 1,200 healthcare facilities. For information about QuadraMed, visit www.quadramed.com.

About LifeMed ID, Inc.

LifeMed ID is a patient identity company based in Citrus Heights, CA, provides a seamless add-on solution that requires no change in hardware, software, insurance verification or payment vendors, and has been named Gartner’s 2014 “New Cool Vendor” for their nonintrusive, scalable and high ROI solution. LifeMed ID addresses specific healthcare industry challenges such as automating patient identity, record matching, registration bottlenecks, clipboard registration, duplicate records, registration errors, and an increased need for a higher level of privacy and security. LifeMed ID is the U.S. industry leader in integrating the use of patient identity tokens (smart card, magstripe , QR code ID cards, multi-biometrics, NFC/phone, Government and Insurance ID, etc.) into the healthcare workflow providing instant, secure, and private information exchange between caregivers, medical facilities, and patients. This system has been proven to dramatically increase patient satisfaction and safety, improve operational efficiencies and eliminate the creation of duplicate records.

QuadraMed is a registered trademark of QuadraMed Corporation. All other trademarks are the property of their respective owners.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.